Efficacy of Early Pegfilgrastim Administration during Preoperative Docetaxel, Cisplatin, and 5-Fluorouracil Therapy in Esophageal Cancer
Masahiro Takei, Hironori Tsujimoto, Asuma Ide, Risa Kariya, Naoyuki Uehata, Takafumi Suzuki, Seiichiro Fujishima, Keita Kouzu, Yoshihisa Yaguchi, Hideki Ueno · 2026
Read Efficacy of Early Pegfilgrastim Administration during Preoperative Docetaxel, Cisplatin, and 5-Fluorouracil Therapy in Esophageal Cancer by Masahiro Takei, Hironori Tsujimoto, Asuma Ide, Risa Kariya, Naoyuki Uehata, Takafumi Suzuki, Seiichiro Fujishima, Keita Kouzu, Yoshihisa Yaguchi, Hideki Ueno (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13453508.txt.
Description
Masahiro Takei and nine co-authors ask whether giving a white cell booster early works better than the standard timing during strong chemotherapy for esophageal cancer. The drug, pegfilgrastim, guards against dangerous drops in infection fighting cells. Their 2026 study looks back at 50 treatment cycles in 28 patients getting a three drug mix before surgery.
Patients split into two groups by timing: the booster on day 3 or on day 7 of each cycle. Early dosing cut low white cell counts from 64 percent to 14 percent of cycles. Fever with low counts fell from 36 percent to 7 percent, and severe gut side effects eased as well. Patients on the early plan also ate better and lost less weight and salt. The authors back day 3 dosing as the safer, kinder plan.
Catalog record
| CREATOR | Masahiro Takei, Hironori Tsujimoto, Asuma Ide, Risa Kariya, Naoyuki Uehata, Takafumi Suzuki, Seiichiro Fujishima, Keita Kouzu, Yoshihisa Yaguchi, Hideki Ueno |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23941 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |